GlassScriptPhysician profile
Sean Nochimson
NPI 1396124780
$3,753.64
in general payments reported to CMS, 2019-2025
28 companies · $836 in 2025
The $836 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $786 · 2021: $716 · 2022: $422 · 2023: $482 · 2024: $309 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $711.58 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $475.58 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $373.55 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $257.63 | 2020-2023 | Otezla, Repatha, Evenity |
| Abbvie INC. | $197.76 | 2021-2022 | |
| Allergan, INC. | $192.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $180.98 | 2020-2021 | |
| Lilly USA, LLC | $173.43 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $147.74 | 2020-2022 | |
| Pfizer INC. | $147.53 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.32 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $110.10 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.59 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $102.20 | 2022-2023 | |
| Glaxosmithkline, LLC. | $88.51 | 2020-2024 | Arexvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $71.41 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $68.57 | 2020-2021 | |
| Radius Health, INC. | $32.91 | 2019-2020 | |
| Dexcom, INC. | $31.71 | 2021-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.33 | 2020 | |
| Exact Sciences Corporation | $24.98 | 2025 | The Cologuard Plus Collection Kit |
| Eisai INC. | $23.33 | 2025 | |
| Bausch Health US, LLC | $15.44 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.94 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $14.67 | 2020 | |
| Redhill Biopharma INC. | $14.65 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2025 | |
| Sanofi Pasteur INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Nochimson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.